We intend to maximize the value of the promising drug candidates that result from our novel drug discovery research. To that end, we carefully evaluate business development opportunities, seeking collaborations that have significant potential to build value and create returns for our investors. Our current collaborations are outlined below. We continue to explore potential collaborations for our drug candidates.
United Therapeutics Corporation – Ralinepag for Pulmonary Arterial Hypertension (PAH) (Ph 3)
We and United Therapeutics entered into an Exclusive License Agreement related to ralinepag, which is currently being evaluated for the treatment of PAH. Under the agreement, we granted United Therapeutics an exclusive, global, perpetual, irrevocable license to develop, manufacture and commercialize ralinepag in any formulation for any indication. United Therapeutics will be responsible for development, manufacture and commercialization of the product.
In addition to an upfront payment of $800 million we received from United Therapeutics upon closing, we are also eligible to receive up to an aggregate of $400 million in regulatory milestone payments related to ralinepag, as well as low double-digit, tiered royalties on net sales of ralinepag, subject to certain adjustments for third party license payments.
Everest Medicines Limited –Etrasimod in Greater China and Select Asian Countries (Ph 3)
We and Everest Medicines have a development and commercialization partnership for etrasimod in mainland China, Taiwan, Hong Kong, Macau, and South Korea (the “Territories”). The goal is to leverage Everest capabilities in the evolving regulatory landscape in China to enhance the drug approval process related to transformative foreign drugs. Under the terms of the agreement, Arena has granted Everest exclusive rights to develop and commercialize etrasimod in the Territories. In return, Arena received an upfront payment and is eligible to receive development and commercial milestone payments as well as royalties on net annual sales of etrasimod. The parties plan to collaborate on development on both products; however, Everest is generally responsible for funding development and commercialization in the Territories.
Boehringer Ingelheim International GmbH – Undisclosed Target (Preclinical)
We and Boehringer Ingelheim have a Research and Licensing Agreement to conduct joint research to identify drug candidates targeting a GPCR that belongs to the group of orphan CNS receptors. The goal is to identify additional drug candidates that are suitable for continued research and development as therapeutic compounds for various disease indications, with the initial focus expected to be psychiatric diseases such as schizophrenia. The agreement grants Boehringer Ingelheim exclusive worldwide rights to develop, manufacture and commercialize products resulting from the collaboration.
Eisai – BELVIQ® (lorcaserin HCI) (Commercial)
We discovered and developed lorcaserin (BELVIQ and BELVIQ XR), which is currently marketed by Eisai or its distributors in the United States, or US, and certain other countries for weight loss. We have granted an exclusive, royalty-bearing license, or transferred intellectual property or other rights, to develop, manufacture and commercialize BELVIQ(lorcaserin) in all countries and territories of the world. Eisai assumed Arena’s exclusive manufacturing and supply agreements with third-parties to develop and market lorcaserin in South Korea, Taiwan and Israel. Eisai has agreed to make tiered royalty payments to us on the net sales of lorcaserin.
For Belviq®-related inquires please contact Eisai.
Last updated as of 8/7/19